上海之江生物科技股份有限公司关于2026年度日常关联交易预计的公告

Group 1 - The core viewpoint of the announcement is that the expected related party transactions for 2026 are necessary for the company's normal operations and will not affect its independence or harm the interests of shareholders [1][2][6] - The expected amount and categories of related party transactions for 2026 are based on market prices and are essential for the company's business development [3][5] - The independent directors have reviewed and approved the related party transactions, confirming that they align with the company's interests and do not impact its independence [2][4] Group 2 - The company plans to use up to RMB 860 million of temporarily idle raised funds for cash management, ensuring it does not affect the implementation of investment projects [12][13][19] - The investment will focus on high-safety, liquidity-friendly products with a maturity of no more than 12 months, including guaranteed financial products and structured deposits [12][18] - The company aims to enhance the efficiency of fund usage and maximize shareholder returns through this cash management strategy [14][29][30]